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The interaction of propofol and human serum albumin (HSA) has been investigated
by UV-absorption, ﬂuorescence spectroscopy and Fourier transform infrared (FT-IR)
spectroscopy. Propofol has shown a strong ability to quench the intrinsic ﬂuorescence of
HSA through a static quenching procedure. The binding constant (k) is estimated at a
low value of 2.55×103 M−1 at 293K. FT-IR spectroscopy with Fourier self-deconvolution
technique was used to determine the protein secondary structure in the amide regions
I, II and III. The observed spectral changes of HSA-propofol complex indicate a larger
intensity decrease in the absorption band of α-helix relative to that of β-sheets. This
variation in intensity is related indirectly to the formation of H-bonding in the complex
molecules, which accounts for the diﬀerent intrinsic propensities of α-helix and β-sheets.
Keywords: Propofol; binding constant; protein secondary structure; FT-IR spectroscopy.
1. Introduction
Propofol is chemically described as 2, 6-diisopropylphenol as shown in Fig. 1(a).1 It
is a short-acting intravenous anesthetic drug for controlled sedation, short surgical
procedures, and maintenance of anesthesia when administered by infusion.2,3 The
clinical dose for healthy adults less than 55 years of age is 100 to 200mcg/kg/min
(6 to 12mg/kg/h).4 The use of propofol has been shown to restore cerebrovascu-
lar pressure autoregulation in patients during cardiopulmonary bypass.5,6 This can
be explained as a result of the cerebral vasoconstrictor eﬀect of this drug, since
vasoconstrictors are generally known to increase vascular smooth muscle tone and
therefore to improve pressure autoregulation.7 It is suggested that anesthetics drugs
induce their eﬀects in the central nervous system by binding directly to protein
targets.8 Most of these expectations come from electrophysiological measurements,
coupled more recently with the techniques of molecular genetics. Even though these
approaches are needed to understanding the eﬀect of general anesthetics, they can
give little information on the forces that are involved in anesthetic–protein interac-
tions and provide no information on anesthetic binding sites.9
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(a) (b)
Fig. 1. Chemical structure of propofol (a) and stereo view of HSA illustrating the overall topology
and secondary structure (b).
Human serum albumin (HSA) is the most abundant protein in blood plasma
which has a very eﬀective role in transporting various compounds such as fatty acids,
hormones, metabolites and large number of drugs. HSA serves as the major soluble
protein constituent of the circulatory system. It contributes to colloid osmotic blood
pressure, and it can bind and carry drugs which are poorly soluble in water.10
The three-dimensional structure of HSA is determined through X-ray crystallo-
graphic measurements shown in Fig. 1(b).11 HSA consists of a single polypeptide
chain of 585 amino acids. Its structure contains three homologous domains (labeled
as I, II and III), each of which is composed of two subdomains, A and B, having six
and four α-helices, respectively.12 The binding sites of albumin are distributed all
over the molecule. Strong binding reduces the concentrations of free drugs in plasma,
while weak binding can cause a short lifetime and poor distribution of the drugs.
Multiple drug binding sites have been reported for HSA by several researchers.14–19
The main binding sites for ligands in HSA are located in hydrophobic cavities in
subdomains IIA and IIIA, which are labeled as site I and site II, respectively.20 Site
I is mainly known for a strong hydrophobic interaction with most neutral, bulky,
heterocyclic compounds, while site II is reserved for other diﬀerent interactions
such as dipole–dipole, van der Waals, and/or hydrogen-bonding. HSA contained a
single intrinsic tryptophan residue (Trp 214) in domain IIA and its ﬂuorescence is
sensitive to the ligands bound nearby.21,22 Therefore, it is suitable to be used as a
probe to investigate the binding properties of drugs with HSA.
According to what have been reported, more than 50% of a clinically admin-
istered general anesthetic will be bound to serum albumin, and for the bind-
ing of propofol with HSA two sites.9 One is located in subdomain IIIA while
the other is located in subdomain IIIB. In both cases the aromatic ring lies
B
io
ph
ys
. R
ev
. L
et
t. 
20
10
.0
5:
20
9-
22
6.
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.w
or
ld
sc
ie
nt
ifi
c.c
om
by
 D
r. 
Sa
qe
r D
ar
w
ish
 o
n 
10
/0
7/
13
. F
or
 p
er
so
na
l u
se
 o
nl
y.
January 10, 2011 9:17 WSPC/S1793-0480 204-BRL S1793048010001202
Spectroscopic Study of Propofol Binding to Human Serum Albumin 211
within apolar pocket, with the phenolic hydroxyl group making a hydrogen bond
with a main-chain carbonyl oxygen in case (IIIA) and with a serine hydroxyl in
case (IIIB).
FT-IR spectroscopy has been a valuable method for the analysis of protein
secondary structures for many years. It requires only small amounts of proteins
(1mM) in a variety of environments, to yield relatively high quality spectra. Infrared
spectroscopy provides measurements of molecular vibrations due to the speciﬁc
absorption of infrared radiation by chemical bonds. The form and frequency of
the amide I band, which is assigned to the C=O stretching vibration within the
peptide bonds is very characteristic for the structure of the studied protein.23 From
the band secondary structure, component peaks (α-helix, β-strand) can be derived
and the analysis of this single band allows elucidation of conformational changes
with high sensitivity.
This work will focus on the mid-range infrared, which covers the frequency range
from 4000 to 400 cm−1. This wavelength region includes three bands that arise from
the conformational sensitive vibrations within the peptide backbone namely amide
I, II and III. Amide I band is the most widely used and can provide information on
secondary structure composition and structural stability.
Other spectroscopy techniques are usually used in studying the interaction of
drugs and proteins. Fluorescence and UV-visible spectroscopy are commonly used
because of their high sensitivities, rapidity and ease of implementation. Several
reports have been published studying the interaction of proteins with drugs by
ﬂuorescence techniques.24–30
The binding of propofol to HSA was investigated by means of UV-absorption
spectroscopy, ﬂuorescence spectroscopy, and FT-IR spectroscopy. Spectroscopic evi-
dence regarding the drug binding mode, drug binding constant and the eﬀects of
propofol on the protein secondary structure are provided in this work.
2. Materials and Methods
Propofol with molecular weight 178.3 gmole−1 in liquid form, phosphate buﬀer
saline (pH 7.4) and HSA (fatty acid free) were purchased from Sigma chemical
company and used without further puriﬁcation. Phosphate buﬀer saline has been
dissolved in distilled water before use.
2.1. Preparation of stock solutions
HSA was dissolved in phosphate buﬀer saline (80mg/ml). The concentration of
HSA in the buﬀer solution was prepared using its list molecular weight of 66.5 kDa.
The solutions of propofol with the following concentrations 0.48, 0.96, 1.92, 2.88,
3.84mM were prepared by dissolving the drug in double distilled water. In the ﬁnal
step drug solution was added to the protein solution of equal volume to attain the
desired drug concentrations of 0.24, 0.48, 0.96, 1.44, 1.92mM with a ﬁnal protein
concentration of 40mg/ml. The propofol concentrations used in our study are in
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the range and above clinical concentrations.4 For the dry ﬁlm preparation, 50µl of
propofol and HSA solution were deposited on a silicon window and incubated for
24 hours (at 25◦C) before spectroscopic measurements were taken.
2.2. UV-visible absorption spectra
The absorption spectra were obtained by the use of a NanoDrop ND-1000 spec-
trophotometer. The studied samples were homogenous solutions of free HSA
(40mg/ml) and for its complexes with propofol concentrations of 0.24, 0.48, 0.96,
1.44, and 1.92mM. The measurements were repeated for all the samples and no
signiﬁcant diﬀerences were observed.
2.3. Fluorescence
The ﬂuorescence measurements were performed by a NanoDrop ND-3300 ﬂuo-
rospectrometer at 25◦C. The excitation source comes from one of three solid-state
light emitting diodes (LEDs). The excitation source options include UV LED with
maximum excitation at 365nm, blue LED with excitation at 470 nm, and white
LED from 500–650nm excitation. A 2048-element CCD array detector covering
400–750nm, is connected by an optical ﬁber to the optical measurement surface.
The excitation is done at the wavelength of 360 nm and the maximum emission
wavelength is at 443nm.
2.4. FT-IR spectroscopic measurements
All infrared spectra were recorded at room temperature on a Bruker IFS 66/S
spectrophotometer equipped with a liquid nitrogen-cooled MCT detector and a
KBr beam splitter. Dry ﬁlm samples are prepared after two hours of incubation for
the HSA and HSA-propofol solution at room temperature.
The absorption spectra were obtained in the wave number range of 4000–
400 cm−1. A spectrum was taken, using silicon windows with a spectral resolution
of 4 cm−1 and 100 scans to increase the signal-to-noise ratio. The aperture used is
8mm, since we found that this aperture gave best signal-to-noise ratio. Baseline
correction, normalization and peak areas calculations were performed for all the
spectra by OPUS software. The peak positions were determined using the second
derivative of the spectra.
The infrared spectra of free HSA and the propofol–HSA complexes were
obtained in the region of 2500–1000cm−1. For the net interaction eﬀect, the diﬀer-
ence spectra [(protein and propofol solution) − (protein solution)] were generated
using the featureless region of the protein solution 2200–1800cm−1 as an internal
standard.29 The accuracy of this subtraction method is tested using several control
samples with the same protein or drug concentrations, which result in a ﬂat base
line formation. The obtained spectral diﬀerences were used here, to investigate the
nature of the drug–HSA interaction.
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3. Results and Discussion
3.1. UV-Vis absorption spectroscopy
The propofol–HSA binding constant is determined using UV absorption
spectroscopy as reported for several drug–protein complexes.30–32 The absorp-
tion spectra for diﬀerent concentrations of propofol in HSA are shown in Fig. 2.
The interaction between propofol and HSA in aqueous solution, leads to establish
Eqs. (1) and (2) as follows26:
HSA + propofol↔ propofol: HSA, (1)
K = [propofol: HSA]/[propofol][HSA]. (2)
The absorption data were treated using linear reciprocal plots based on the
equation33
1
A−A0 =
1
A∞ −A0 +
1
K[A∞ −A0] ·
1
L
, (3)
where A0 corresponds to the initial absorption of protein at 280nm in the absence
of ligand, A∞ is the ﬁnal absorption of the ligated-protein, and A is the recorded
absorption at diﬀerent propofol concentrations (L). The double reciprocal plot of
1/(A − A0) vs 1/L is linear (Fig. 3) and the overall binding constant (K) can
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Fig. 2. UV-absorbance spectra of HSA with diﬀerent concentrations of propofol (a = 1.92mM,
b = 1.44mM, c = 0.96mM, d = 0.48mM, e = 0.24mM, f = 0.00mM, and g propofol).
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Fig. 3. A plot of 1/(A − A0) vs 1/L for HSA with diﬀerent concentrations of propofol.
be estimated from the ratio of the intercept to the slope to be 2.55 × 103M−1.
This binding constant value shows a relatively weak propofol–HSA interaction in
comparison to other drug–HSA complexes with binding constants in the range of
105 and 106M−1.13 It has been shown that propofol binds with highest aﬃnity
to a site in subdomain IIIA.9 The relative weakness of the binding constant may
contribute to making propofol an ultra-short-acting sedative-hypnotic agent. The
reason for the low stability of the propofol–HSA complexes can be attributed to
hydrogen bonding interaction between protein donor atoms and the propofol polar
groups or to an indirect drug–protein interaction through water molecules.32 It has
been proposed that anesthetics may exert their eﬀects on proteins at the molecular
level by attenuating the movement of the local amino acid side chains, leading to
stabilizing certain protein conformations and, hence, aﬀecting its function.34
3.2. Fluorescence spectroscopy
The ﬂuorescence of HSA results from the tryptophan, tyrosine, and phenylalanine
residues. The decrease in ﬂuorescence of HSA is mainly attributed to change in the
environment of the protein ﬂuorophores caused by the presence of the ligand.35 In
our experiment the ﬂuorescence sensor is based on intramolecular charge transfer
(ICT), which is highly sensitive to the polarity of microenvironment.36,37 The ﬂuo-
rescence emission spectra of the bound drug–HSA has been aﬀected by the presence
of ligands which bind speciﬁcally to the HSA. This leads to the use of the drug as
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Fig. 4. Fluorescence emission spectra of HSA in the absence and presence of propofol in these
concentrations (a = 0.0mM, b = 0.24mM, c = 0.48mM, d = 0.96mM, e = 1.44mM and f = 1.92).
a ﬂuorescent probe for some biochemical systems like proteins to determine the
environment at the drug binding site and the binding constant between drug and
HSA.38,39 The ﬂuorescence spectra of HSA incubated with various concentrations of
propofol (0.24, 0.48, 0.96, 1.44, and 1.92mM) are shown in Fig. 4. The ﬂuorescence
intensity of HSA decreased regularly with the increasing of propofol concentration,
while the peak position shows little or no change at all indicating no change in the
required bonding energy for this peak.
The dynamic quenching process can be described by the Stern–Volmer
equation24
F0
F
= 1 + Kqτ0(L) = 1 + KSV (L), (4)
where F and F0 are the ﬂuorescence intensities with and without quencher, Kq is
the quenching rate constant of the biomolecule, KSV is the Stern–Volmer quench-
ing constant, τ0 is the average lifetime of the biomolecule without quencher, and
L is the concentration of propofol. As can be seen from Fig. 5, the Stern–Volmer
plot is linear and the slope is equal to KSV (9.686 × 106 Lmol−1). Fluorescence
quenching can be induced by diﬀerent mechanisms, which were usually classiﬁed
into dynamic quenching and static quenching. Dynamic quenching arises from col-
lisional encounters between the ﬂuorophore and the quencher, and static quenching
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Fig. 5. Stern–Volmer plot for propofol–HSA system.
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Fig. 6. Plot of 1/(F0 − F ) vs 1/[L∗105].
resulting from the formation of a ground state complex between the ﬂuorophore
and the quencher.40
The quenching rate constant Kq, can be calculated using the ﬂuorescence
lifetime of 10−8 s for HSA.41
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The obtained value of 9.686 × 1014 Lmol−1 s−1 is much larger than the
maximum dynamic quenching constant for various quenchers with biopolymer
(2 × 1010 Lmol−1 s−1).42 This result conﬁrms that a static quenching is dominant
in the formed complexes.43
When the static quenching equation is used40
1
F0 − F =
1
F0K(L)
+
1
F0
, (5)
where K is the binding constant of propofol with HSA. The value of K can be deter-
mined from the slope and the intercept in Fig. 6. The value of K is 2.55× 03 M−1,
which agrees well with the value obtained earlier by UV spectroscopy and sup-
ports the eﬀective role of static quenching. The highly eﬀective quenching con-
stant in this case has lead to a lower value of binding constant between the drug
and HSA suggests the formations of eﬀective hydrogen bonding between propofol
and HSA.
3.3. FT-IR spectroscopy
Infrared spectra of proteins exhibit a number of amide bands, which represent
diﬀerent vibrations of the peptide moiety. The amide group of proteins and polypep-
tides presents characteristic vibrational modes (amide modes) which are sensitive
to the protein conformation and largely been constrained to group frequency
interpretations.44 Amide I (1700–1600cm−1) is mainly due to the C=O stretching
vibration, amide II (1600–1480cm−1 region) is due to the coupling of the N–H in-
plane bending and C–N stretching modes, and amide III (1330–1220cm−1 region) is
attributed to the C–N stretching coupled to the in-plane N–H bending mode.45–47
Furthermore, other bands at 1300–900cm−1 were assigned to C–O bending modes of
saccharides (glucose, lactose and glycerol), the peaks at 1430–1360cm−1 attributed
to vibrations of certain amino acids chains and 1480–1430cm−1 is attributed to
fatty acids, phospholipids and triglycerides.48,49
The second derivative of the FT-IR spectrum for HSA free, and the spectra for
HSA with diﬀerent concentrations of propofol are shown in Fig. 7, where the spec-
tra are dominated by the absorbance bands of amide I and amide II at 1656 and
1544 cm−1, respectively. The peak positions of amide I bands in HSA infrared spec-
trum shifted as listed in Table 1: 1615 to 1611 cm−1, 1624 to 1627 cm−1, 1636 to
1642 cm−1, 1682 to 1678 cm−1, 1655 to 1659 cm−1 and 1695 to 1691 cm−1 after
interaction with propofol. The changes of the peak positions and peak shapes
demonstrated changes in the secondary structure of HSA due to its interaction
with propofol. In amide II region some of the peak positions have shifted in the
following order: 1543 to 1549 cm−1, 1564 to 1567cm−1, 1577 to 1584 cm−1 and 1594
to 1597 cm−1. In the amide III region little or no change of the peak positions have
been observed. The minor changes in peak positions can be attributed to the eﬀect
of the newly imposed H-bonding between the drug molecules and the protein. It is
suggested that, the shift to a higher frequency for the major peak in amide I region
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Fig. 7. Spectra of (A) HSA-free (second derivative) and (B) shows the spectra of (a, b, c, d, e,
and f) HSA–propofol with concentrations (0.0, 0.24, 0.48, 0.96, 1.44 and 1.92mM).
(1655 to 1659) has resulted from new H-bonding, which formed as the C–N bond
assumed partial double bond character due to a ﬂow of electrons from the C=O to
the C–N bond.50
The component bands of amide I were attributed according to the
well-established assignment criterion.51,52 The bands range 1640–1610cm−1 are
generally assigned to β-sheet, 1650–1640cm−1 to random coil, 1658–1650cm−1
to α-helix and 1700–1660cm−1 to β-turn structure. As for amide II, the absorp-
tion band consists of four components and assigned in the following order: 1500–
1488 cm−1 to β-sheets, 1525–1504cm−1 to random coil 1560–1527cm−1 to α-helix
and 1585–1564cm−1 to turn structure.53 The component bands of amide III have
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Table 1. Bands assignments in the absorbance spectra of HSA with diﬀerent propofol
concentrations for amide I–III regions.
Bands HSA HSA-prop HSA-prop HSA-prop HSA-prop HSA-prop
free 0.24mM 0.48mM 0.96mM 1.44mM 1.92mM
Amide I
(1600–1700)
1615 1612 1611 1616 1617 1611
1624 1627 1628 1626 1625 1627
1636 1640 1642 1638 1637 1642
1655 1657 1658 1657 1656 1659
1682 1680 1677 1681 1682 1678
1695 1692 1691 1693 1693 1691
Amide II
(1480–1600)
1515 1515 1514 1516 1516 1514
1532 1532 1531 1532 1532 1531
1543 1549 1549 1548 1546 1549
1564 1568 1566 1570 1571 1567
1577 1583 1583 1590 1578 1584
1594 1597 1598 1594 1592 1597
Amide III
(1220–1330)
1226 1226 1226 1226 1226 1226
1243 1242 1243 1243 1243 1242
1268 1267 1269 1268 1268 1268
– 1278 1278 1275 1275 1275
1293 1294 1293 1294 1293 1293
1314 1311 1313 1314 1313 1313
been assigned as follows: α-helix 1330–1290cm−1, β-turn 1290–1270cm−1, random
coil 1270–1250cm−1 and β-sheet 1250–1220cm−1.52
Most investigations have concentrated on amide I band assuming higher
sensitivity to the change of protein secondary structure.54 However, it has been
reported that amide II band spectrum reveals enough information and could be
used alone for secondary structure prediction in place of amide I.55,56
Others have reported that amide III is not directly aﬀected by the strong water
band and therefore it is more suited for structure determinations.57
The diﬀerence spectra [(protein and propofol) − (protein)] were obtained for
amide I, amide II, and amide III regions to investigate the intensity variations and
the results are shown in Figs. 8 and 9, respectively. In the amide I and amide II
regions, two strong negative features at 1652 and 1548 cm−1 were observed at
low propofol concentration (0.48mM). These two negative features became even
stronger at higher concentrations with a little shift in their positions. In the
amide III region, two strong negative features at 1242 and 1315 cm−1 were observed
at low propofol concentration and with concentration increasing these features show
more strength. The observed negative features are attributed to the decrease of
intensities at amide I band at 1655 cm−1 and amide II band at 1543 cm−1 as a
result of drug interaction (H-bonding) with protein C=O and C–N groups.26
In this work a quantitative analysis of the protein secondary structure for the
free HSA and propofol–HSA complex in dehydrated ﬁlms is determined from the
shape of amide I, II and III bands. Infrared Fourier self-deconvolution with sec-
ond derivative resolution and curve ﬁtted procedures,58,59 were applied to increase
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Fig. 8. FT-IR spectra (top two curves) and diﬀerence spectra of HSA and its complexes of
diﬀerent propofol concentrations in the region of 1800–1500 cm−1.
spectral resolution. Therefore it is highly eﬀective in identifying the peak position
and in determining the area of each individual band. The procedure was in general
carried out considering only components detected by second derivatives and has
minimum half widths at half height (HWHH) of 5 cm−1. Based on the above band
assignments, the percentages of each secondary structure of HSA were calculated
from the integrated areas of the component bands in amide I, II and III respectively.
Table 2 shows the content of each secondary structure of HSA before and after the
interaction with propofol at diﬀerent concentrations.
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Fig. 9. FT-IR spectra (top two curves) and the diﬀerence spectra of HSA and its complexes of
diﬀerent propofol concentrations in the amide III region.
Figures 10 and 11 reveal second derivative resolution enhancement and curve-
ﬁtted for amide I and amide II regions, respectively. The second derivative spectra
and the secondary structure of the free human serum albumin are shown in (A,
B), while its propofol complexes are shown in (C, D) for dehydrated ﬁlms. It is
generally accepted that infrared spectra of proteins in ﬁlms and in solution may
display distinct diﬀerences, but these diﬀerences are due to the presence or absence
of the water or buﬀer molecules that imprint their mark on the spectra. It has been
shown that the structural information content is of the same quality in ﬁlms and
in solution with an (error of <1%) for both systems.60
The percentage values for the components of amid I of free HSA are consis-
tent with the results of other recent spectroscopic studies.61–63 The results of
amide II and amide III showed similar trends in their percentage values to that
of amide I. The decrease of α-helix percentage with the increase of propofol con-
centrations is evident in the calculations and this trend is consistent in the three
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Table 2. Secondary structure determination for amide regions (I–III) in HSA and its propofol
complexes.
Bands HSA HSA-prop HSA-prop HSA-prop HSA-prop HSA-prop
free 0.24mM 0.48mM 0.96mM 1.44mM 1.92mM
Amide I
β-sheets (cm−1)
(1603–1635)
(1687–1700)
16 32 32 32 36 39
Random (cm−1)
(1635–1645)
15 6 6 5 5 5
α-helix (cm−1)
(1648–1670)
55 52 52 50 49 46
Turn (cm−1)
(1670–1685)
14 10 10 13 10 10
Amide II
β-sheets (cm−1)
(1488–1504)
(1585–1600)
18 23 25 27 29 29
Random (cm−1)
(1504–1525)
14 15 14 14 15 15
α-helix (cm−1)
(1527–1560)
50 47 46 45 43 42
Turn (cm−1)
(1564–1585)
18 15 15 14 13 14
Amide III
β-sheets (cm−1)
(1220–1250)
17 22 22 21 20 21
Random (cm−1)
(1250–1270)
15 15 16 16 17 17
Turn (cm−1)
(1270–1290)
18 18 18 20 21 21
α-helix (cm−1)
(1290–1330)
50 45 44 43 42 41
amide regions. However, for the β-sheet the relative percentage has increased with
increasing propofol concentrations. The reduction of α-helix intensity percentage
and the increase of β-sheets are speculated to be due to the unfolding of the pro-
tein in the presence of propofol as a result of the formation of H-bonding between
HSA and the drug. The steric blocking eﬀect can contribute an enthalpic stabi-
lization to intraprotein hydrogen bonds and disfavors peptide to catalyst com-
plexation in hydrogen exchange reactions and peptide to peptide H-bonding in
the helical main chain conformation but not in β-strands.64 The newly formed
H-bonding result in the C–N bond assuming partial double bond character due
to a ﬂow of electrons from the C=O to the C–N bond which decreases the
intensity of the original vibrations.50 It seems that the H-bonding aﬀects more
of the original bonding in α-helix than in β-sheets depending on the accessibil-
ity of the solvent and on propensities of α-helix and β-sheets of the protein.65
The hydrogen bonds in α-helix are formed inside the helix and parallel to the
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Fig. 10. Second-derivative resolution enhancement and curve-ﬁtted amide I region (1700–
1612 cm−1) and secondary structure determination of the free human serum albumin (A, B)
and its propofol complexes (C, D) with 1.92mM drug concentration.
helix axis, while for β-sheet the hydrogen bonds take position in the planes of
β-sheets as the preferred orientations especially in the anti-parallel sheets. The
restrictions on the formation of hydrogen bonds in β-sheet relative to the case in
α-helix explains the larger eﬀect on reducing the intensity percentage of α-helix
to that of β-sheet. Similar conformational transitions from an α-helix to β-sheet
structure were reported for the protein unfolding upon protonation and heat
denaturation.66,67
In summary, the binding of propofol to HSA has been investigated by UV-visible
absorption spectroscopy, ﬂuorescence spectroscopy and by FT-IR spectroscopy.
From the UV and ﬂuorescence investigations we determined values for the binding
constant and the quenching constant. The results indicate that the intrinsic ﬂuo-
rescence of HSA was quenched by propofol through static quenching mechanism.
Analysis of the FT-IR spectra in the three amide regions (I, II and III) reveals that
HSA–propofol interaction induces intensity reduction in the absorption bands of
α-helix and β-sheets components with diﬀerent proportionality due to the diﬀerent
accessibility of H-bond formation in these components.
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Fig. 11. Second-derivative resolution enhancement and curve ﬁtted amide II (1600–1480 cm−1)
and secondary structure determination of the free human serum albumin (A, B) and its propofol
complexes (C, D) with 1.92mM drug concentration.
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